Lauren E Galbraith1, Paul E Ronksley1, Lianne J Barnieh2, Joanne Kappel3, Braden J Manns4, Susan M Samuel2, Min Jun2, Rob Weaver2, Nadine Valk5, Brenda R Hemmelgarn6. 1. Departments of *Community Health Sciences and. 2. Medicine, University of Calgary, Calgary, Canada; 3. Division of Nephrology, University of Saskatchewan, Saskatoon, Canada; and. 4. Departments of *Community Health Sciences and Medicine, University of Calgary, Calgary, Canada; 5. Kidney Foundation of Canada, Ottawa, Canada. 6. Departments of *Community Health Sciences and Medicine, University of Calgary, Calgary, Canada; Brenda.Hemmelgarn@albertahealthservices.ca.
Abstract
BACKGROUND AND OBJECTIVES: The effectiveness of targeted screening for identification of CKD is largely unknown. The See Kidney Disease (SeeKD) targeted screening project aimed to determine the prevalence of unrecognized CKD in Canada. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The SeeKD project was conducted across Canada using a convenience sample approach and events to identify adults with risk factors for CKD (i.e., diabetes, hypertension, vascular disease, family history of kidney problems, etc.). Participants with at least one risk factor received a point-of-care creatinine measurement to identify unrecognized CKD (CKD-Epidemiology Collaboration eGFR <60 ml/min per 1.73 m(2)). Baseline information included clinical characteristics, sociodemographics, and health knowledge. Semistructured telephone interviews were conducted with each Kidney Foundation of Canada branch (regionalized locations) after the screening events to characterize local screening strategies, which were subsequently categorized as individual-targeted (specifically targeting individuals at risk of CKD) and community-targeted (event in a community location in proximity to a high-risk population). We calculated the prevalence of unrecognized CKD overall, and by screening strategy. RESULTS: Between January 2011 and February 2014, 6329 Canadians participated in SeeKD screening events. Participants were predominantly female (65.3%), middle-aged (mean, 58.5 years), and the majority (88.9%) self-reported at least one risk factor for CKD. Of participants with at least one risk factor, 92.3% (n=5194) were screened, of whom 18.8% (95% confidence interval [95% CI], 17.8 to 19.9) had unrecognized CKD; the majority (13.8%) had stage 3a CKD (eGFR=45-60 ml/min per 1.73 m(2)). The prevalence of unrecognized CKD was higher for branches with individual versus community-targeted events (21.9% [95% CI, 20.5 to 23.4] versus 14.7% [95% CI, 13.2 to 16.2]). CONCLUSIONS: Targeted screening identified a high proportion of individuals with risk factors for CKD and a high prevalence of unrecognized CKD. Future research will evaluate the ability of targeted screening to promote self-management behaviors addressing priorities for people with CKD.
BACKGROUND AND OBJECTIVES: The effectiveness of targeted screening for identification of CKD is largely unknown. The See Kidney Disease (SeeKD) targeted screening project aimed to determine the prevalence of unrecognized CKD in Canada. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The SeeKD project was conducted across Canada using a convenience sample approach and events to identify adults with risk factors for CKD (i.e., diabetes, hypertension, vascular disease, family history of kidney problems, etc.). Participants with at least one risk factor received a point-of-care creatinine measurement to identify unrecognized CKD (CKD-Epidemiology Collaboration eGFR <60 ml/min per 1.73 m(2)). Baseline information included clinical characteristics, sociodemographics, and health knowledge. Semistructured telephone interviews were conducted with each Kidney Foundation of Canada branch (regionalized locations) after the screening events to characterize local screening strategies, which were subsequently categorized as individual-targeted (specifically targeting individuals at risk of CKD) and community-targeted (event in a community location in proximity to a high-risk population). We calculated the prevalence of unrecognized CKD overall, and by screening strategy. RESULTS: Between January 2011 and February 2014, 6329 Canadians participated in SeeKD screening events. Participants were predominantly female (65.3%), middle-aged (mean, 58.5 years), and the majority (88.9%) self-reported at least one risk factor for CKD. Of participants with at least one risk factor, 92.3% (n=5194) were screened, of whom 18.8% (95% confidence interval [95% CI], 17.8 to 19.9) had unrecognized CKD; the majority (13.8%) had stage 3a CKD (eGFR=45-60 ml/min per 1.73 m(2)). The prevalence of unrecognized CKD was higher for branches with individual versus community-targeted events (21.9% [95% CI, 20.5 to 23.4] versus 14.7% [95% CI, 13.2 to 16.2]). CONCLUSIONS: Targeted screening identified a high proportion of individuals with risk factors for CKD and a high prevalence of unrecognized CKD. Future research will evaluate the ability of targeted screening to promote self-management behaviors addressing priorities for people with CKD.
Authors: Wendy Weinstock Brown; Rosalind M Peters; Suzanne E Ohmit; William F Keane; Allan Collins; Shu-Chen Chen; Karren King; Michael J Klag; Donald A Molony; John M Flack Journal: Am J Kidney Dis Date: 2003-07 Impact factor: 8.860
Authors: Adam T Whaley-Connell; James R Sowers; Lesley A Stevens; Samy I McFarlane; Michael G Shlipak; Keith C Norris; Shu-Cheng Chen; Yang Qiu; Changchun Wang; Suying Li; Joseph A Vassalotti; Allan J Collins Journal: Am J Kidney Dis Date: 2008-04 Impact factor: 8.860
Authors: A S Levey; R Atkins; J Coresh; E P Cohen; A J Collins; K-U Eckardt; M E Nahas; B L Jaber; M Jadoul; A Levin; N R Powe; J Rossert; D C Wheeler; N Lameire; G Eknoyan Journal: Kidney Int Date: 2007-06-13 Impact factor: 10.612
Authors: Paul Arora; Priya Vasa; Darren Brenner; Karl Iglar; Phil McFarlane; Howard Morrison; Alaa Badawi Journal: CMAJ Date: 2013-05-06 Impact factor: 8.262
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Pankti A Gheewala; Syed Tabish R Zaidi; Matthew D Jose; Luke Bereznicki; Gregory M Peterson; Ronald L Castelino Journal: J Nephrol Date: 2017-02-08 Impact factor: 3.902
Authors: George P Bayliss; Jason Cobb; Brian Decker; Richard Hellman; Nina Vasavada; Lina Mackelaite; Craig Shadur; Titilayo Ilori; Tod Ibrahim; Katlyn Leight; Li-Li Hsiao; Bruce A Molitoris; Mark D Okusa; Mark G Parker Journal: Clin Kidney J Date: 2019-08-22
Authors: Naila A Shaheen; Ahmed Alaskar; Abdulrahman Almuflih; Naif Muhanna; Sufyan Barrak Alzomia; Mohammed A Hussein Journal: Int J Gen Med Date: 2021-10-20
Authors: Lauren Galbraith; Brenda Hemmelgarn; Braden Manns; Susan Samuel; Joanne Kappel; Nadine Valk; Paul Ronksley Journal: Can J Kidney Health Dis Date: 2016-07-20
Authors: Katherine R Tuttle; Frank C Brosius; Matthew A Cavender; Paola Fioretto; Kevin J Fowler; Hiddo J L Heerspink; Tom Manley; Darren K McGuire; Mark E Molitch; Amy K Mottl; Leigh Perreault; Sylvia E Rosas; Peter Rossing; Laura Sola; Volker Vallon; Christoph Wanner; Vlado Perkovic Journal: Diabetes Date: 2020-10-26 Impact factor: 9.461